mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers
Dustin A. Deming(University of Wisconsin–Madison), Richard B. Halberg(University of Wisconsin Carbone Cancer Center)
Cited by 22
Related Papers
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
|Nature Reviews Clinical Oncology|2020|365
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer
|Genome biology|2007|343
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
|Oncogenesis|2015|75
Fisetin and 5‐fluorouracil: Effective combination for <i>PIK3CA</i>‐mutant colorectal cancer
|International Journal of Cancer|2019|41